{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T12:04:09Z","timestamp":1775217849591,"version":"3.50.1"},"reference-count":14,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2025.15220","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T12:28:46Z","timestamp":1754656126000},"page":"1-4","source":"Crossref","is-referenced-by-count":1,"title":["Dialysis independence for a young patient with refractory multiple myeloma treated with teclistamab: A case report"],"prefix":"10.3892","volume":"30","author":[{"given":"Ioannis","family":"Ntanasis\u2011Stathopoulos","sequence":"first","affiliation":[{"name":"Plasma Cell Dyscrasias Unit, Department of Clinical Therapeutics, Alexandra General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilias","family":"Katsadouros","sequence":"additional","affiliation":[{"name":"Plasma Cell Dyscrasias Unit, Department of Clinical Therapeutics, Alexandra General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Malandrakis","sequence":"additional","affiliation":[{"name":"Plasma Cell Dyscrasias Unit, Department of Clinical Therapeutics, Alexandra General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erasmia","family":"Psimenou","sequence":"additional","affiliation":[{"name":"Plasma Cell Dyscrasias Unit, Department of Clinical Therapeutics, Alexandra General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meletios-Athanasios","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"Plasma Cell Dyscrasias Unit, Department of Clinical Therapeutics, Alexandra General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Gavriatopoulou","sequence":"additional","affiliation":[{"name":"Plasma Cell Dyscrasias Unit, Department of Clinical Therapeutics, Alexandra General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"key":"key20250902113609_b1-ol-30-4-15220","doi-asserted-by":"publisher","first-page":"4088","DOI":"10.3390\/jcm10184088","article-title":"BCMA in multiple Myeloma-A promising key to therapy","volume":"10","author":"Kleber","year":"2021","journal-title":"J Clin Med"},{"key":"key20250902113609_b2-ol-30-4-15220","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"key20250902113609_b3-ol-30-4-15220","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1016\/S1470-2045(23)00223-1","article-title":"Management of multiple myeloma-related renal impairment: Recommendations from the International Myeloma Working Group","volume":"24","author":"Dimopoulos","year":"2023","journal-title":"Lancet Oncol"},{"key":"key20250902113609_b4-ol-30-4-15220","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of monoclonal antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"key20250902113609_b5-ol-30-4-15220","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41408-024-01003-z","article-title":"Teclistamab in relapsed refractory multiple myeloma: Multi-institutional real-world study","volume":"14","author":"Mohan","year":"2024","journal-title":"Blood Cancer J"},{"key":"key20250902113609_b6-ol-30-4-15220","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1200\/OP-24-00489","article-title":"Real-world safety and health care resource utilization of teclistamab under an outpatient model for Step-Up dosing administration","volume":"21","author":"Sandahl","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"key20250902113609_b7-ol-30-4-15220","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1182\/blood-2023-181304","article-title":"Teclistamab demonstrates clinical activity in Real-world patients ineligible for the pivotal Majestec-1 trial","volume":"142","author":"Gordon","year":"2023","journal-title":"Blood"},{"key":"key20250902113609_b8-ol-30-4-15220","first-page":"308.e13","article-title":"Safety and efficacy of teclistamab in patients with Relapsed\/Refractory multiple myeloma: A real-world experience","volume":"30","author":"Dima","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"key20250902113609_b9-ol-30-4-15220","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41408-025-01259-z","article-title":"Real-world evaluation of teclistamab for the treatment of relapsed\/refractory multiple myeloma (RRMM): An International Myeloma Working Group study","volume":"15","author":"Tan","year":"2025","journal-title":"Blood Cancer J"},{"key":"key20250902113609_b10-ol-30-4-15220","first-page":"gfaf004","article-title":"Incidence of acute kidney injury in relapsed and refractory multiple myeloma treated with teclistamab versus CAR T-cells","author":"Charkviani","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"key20250902113609_b11-ol-30-4-15220","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1177\/10781552241242022","article-title":"Administration of teclistamab in four patients with multiple myeloma requiring hemodialysis","volume":"30","author":"Khouderchah","year":"2024","journal-title":"J Oncol Pharm Pract"},{"key":"key20250902113609_b12-ol-30-4-15220","doi-asserted-by":"publisher","first-page":"E322","DOI":"10.1002\/ajh.27063","article-title":"Teclistamab in patients with multiple myeloma and impaired renal function","volume":"98","author":"Joiner","year":"2023","journal-title":"Am J Hematol"},{"key":"key20250902113609_b13-ol-30-4-15220","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1111\/bjh.19772","article-title":"Teclistamab for relapsed refractory multiple myeloma patients on dialysis","volume":"205","author":"Lebreton","year":"2024","journal-title":"Br J Haematol"},{"key":"key20250902113609_b14-ol-30-4-15220","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T08:36:12Z","timestamp":1756802172000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2025.15220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":14,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8,8]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2025.15220","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,8]]}}}